Skip to main content
. 2025 Aug 23;150(1):21. doi: 10.1007/s00401-025-02926-y

Table 1.

Description of the main study cohort

Astrocytoma (n = 77) Oligodendroglioma (n = 60) P value
Epidemiological and clinical parameters
Gender n (%) Male 48 (62), Female 29 (38) Male 36 (60), Female 24 (40) 0.8601a
Age at diagnosis median (range) in years 35 (18–62) 43 (16–70) 0.0006b
Primary tumor n (%) 63 (83) 40 (67) 0.0430a
KPS prior to surgery median (range) 100 (70–100) 100 (20–100) 0.2650b
Extent of resection n (%) 0.6901c
 Total 16 (27) 11 (25)
> 90% 12 (20) 6 (14)
< 90% 9 (15) 10 (23)
 Biopsy only 22 (37) 17 (39)
Treatment n (%) 0.3617c
 Radiation + Chemotherapy 53 (69) 36 (62)
 Resection only 13 (17) 7 (12)
 Radiation only 4 (5) 7 (12)
 Chemotherapy only 2 (3) 4 (7)
 Missing data or no treatment 5 (6) 4 (7)
 Observation prior to resection n (%)

na/0 days 59 (77),

18 (23) median 2257 days (2–8115 days)

na/0 days 41 (68),

19 (32) median 1787 days (21–5619 days)

Molecular parameters
 V11b4 HD brain tumor classifier methylation class n (%) Glioma, IDH mutant 77 (100) Glioma, IDH mutant 58 (97), missing 2 (3)
 V11b4 HD brain tumor classifier calibrated score median (range) 0.99 (0.38–0.99) 0.99 (0.42–0.99) 0.6788b
 V11b4 HD brain tumor classifier methylation subclass n (%) Astrocytoma 62 (81), high-grade astrocytoma 15 (19) Oligodendroglioma 1p/19q-codeleted 56 (93), astrocytoma 2 (3), missing 2 (3)
 MGMT promoter methylation status n (%) Unmethylated 17 (22), Methylated 57 (74), missing 3 (4) Unmethylated 4 (7), Methylated 54 (90), missing 2 (3) 0.0156a
Histological parameters
 WHO CNS grade 2 12 (16) 21 (35)
 WHO CNS grade 3 39 (51) 39 (65)
 WHO CNS grade 4 26 (34) na

Epidemiological, clinical and molecular characteristics

P values with numbers in superscript indicating statistical test: aFisher’s exact test, bWilcoxon, cPearson; within “Extent of resection” and “Treatment”, respectively, all categories were considered together for p value computation

P values highlighted in italic indicate significance